As of 2024-12-15, the Intrinsic Value of Basilea Pharmaceutica AG (BSLN.SW) is
39.46 CHF. This BSLN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 40.30 CHF, the upside of Basilea Pharmaceutica AG is
-2.10%.
The range of the Intrinsic Value is 22.28 - 162.62 CHF
39.46 CHF
Intrinsic Value
BSLN.SW Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
22.28 - 162.62 |
39.46 |
-2.1% |
| DCF (Growth 10y) |
21.57 - 141.24 |
36.35 |
-9.8% |
| DCF (EBITDA 5y) |
7.96 - 11.62 |
11.01 |
-72.7% |
| DCF (EBITDA 10y) |
11.35 - 16.05 |
14.62 |
-63.7% |
| Fair Value |
-1.24 - -1.24 |
-1.24 |
-103.07% |
| P/E |
(0.39) - 13.87 |
4.59 |
-88.6% |
| EV/EBITDA |
(4.73) - 16.14 |
1.03 |
-97.4% |
| EPV |
9.70 - 15.77 |
12.74 |
-68.4% |
| DDM - Stable |
(0.62) - (4.41) |
(2.52) |
-106.2% |
| DDM - Multi |
9.73 - 53.96 |
16.54 |
-58.9% |
BSLN.SW Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
530.75 |
| Beta |
1.27 |
| Outstanding shares (mil) |
13.17 |
| Enterprise Value (mil) |
563.47 |
| Market risk premium |
5.10% |
| Cost of Equity |
6.78% |
| Cost of Debt |
5.50% |
| WACC |
6.55% |